3 not yet recruiting, 3 terminated, 2 recruiting, 1 completed. 9 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Not yet recruiting 3, Terminated 3, Recruiting 2, Completed 1 |
| Phase 1 | 4 | Terminated 2, Completed 1, Recruiting 1 |
Follow Follicular Lymphoma (FL): new trials by email Literature Review of Follicular Lymphoma (FL) trials Research Report on Follicular Lymphoma (FL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma Sotoclax in combination with zanubrutinib and rituximab regimen - Follicular Lymphoma (FL) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 52 | 2026-09-01 | 2026-04-24 |
| Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma MDX2003 - Lymphoma, Waldenström Macroglobulinemia (WM) | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 180 | 2026-04-13 | 2026-11-06 |
| Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma TC011 single-arm - Follicular Lymphoma (FL) | Phase 2 | Not yet recruiting | TICAROS Co., Ltd. | 40 | 2026-03-01 | 2026-01-22 |
| Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma Zuberitamab, Bendamustine - Follicular Lymphoma (FL) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 50 | 2025-02-01 | 2025-01-03 |
| Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL Surovatamig - B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL) | Phase 2 | Recruiting | AstraZeneca | 270 | 2024-11-27 | 2026-10-14 |
| A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma MS-553 - Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Terminated | MingSight Pharmaceuticals, Inc | 8 | 2023-02-06 | 2024-07-18 |
| Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) Zandelisib (ME-401) - Follicular Lymphoma (FL), Non Hodgkin Lymphoma | Phase 2 | Terminated | MEI Pharma, Inc. | 169 | 2019-06-25 | 2024-12-31 |
| A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study Tazemetostat - Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) | Phase 1 / Phase 2 | Terminated | Epizyme, Inc. | 58 | 2016-08-30 | 2026-10-28 |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Acalabrutinib, Pembrolizumab - Follicular Lymphoma (FL), CLL | Phase 1 / Phase 2 | Completed | Acerta Pharma BV | 161 | 2015-02-20 | 2026-05-13 |
Lymphoma, Follicular (9) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Non-Hodgkin (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Recurrence (2) · Waldenstrom Macroglobulinemia (2) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Hodgkin Disease (1) · Leukemia, Hairy Cell (1) · Lymphoma (1) · Mesothelioma (1)
Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Lymphoma (8) · Lymphoma, Non-Hodgkin (6) · Lymphoma, B-Cell (4) · Disease Attributes (3) · Hematologic Diseases (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Blood Protein Disorders (2)
Bendamustine Hydrochloride (1) · ME-401 (1) · acalabrutinib (1) · pembrolizumab (1) · tazemetostat (1) · zanubrutinib (1)
Sun Yat-sen University (2) · Acerta Pharma BV (1) · AstraZeneca (1) · Epizyme, Inc. (1) · MEI Pharma, Inc. (1) · MingSight Pharmaceuticals, Inc (1) · ModeX Therapeutics, An OPKO Health Company (1) · TICAROS Co., Ltd. (1)
Australia (4) · China (4) · United States (4) · France (3) · Spain (3) · United Kingdom (3) · Belgium (2) · Germany (2) · Italy (2) · Poland (2) · South Korea (2) · Taiwan (2) · Austria (1) · Brazil (1) · Canada (1)
Qingqing Cai (1) · Won Seok Kim, MD, PhD (1)
2023 (2), 2015 (1), 2018 (1)